746630-34-2

Basic information

• Product Name: 1-(4-BroMo-2,6-difluoro-phenyl)-ethanone
• Synonyms: 1-(4-BroMo-2,6-difluoro-phenyl)-ethanone;4'-bromo-2',6'-difluoroacetophenone
• CAS NO: 746630-34-2
• Molecular Formula: C₈H₅BrF₂O
• Molecular Weight: 235.0255064
• Mol File: 746630-34-2.mol

Chemical Properties

• Boiling Point: 246.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.614±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(4-BroMo-2,6-difluoro-phenyl)-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BroMo-2,6-difluoro-phenyl)-ethanone(746630-34-2)
• EPA Substance Registry System: 1-(4-BroMo-2,6-difluoro-phenyl)-ethanone(746630-34-2)

Safety Data

• Hazardous Substances Data: 746630-34-2(Hazardous Substances Data)

Usage

Uses

1-(4-Bromo-2,6-difluoro-phenyl)-ethanone is used as a chemical intermediate in various industries for the synthesis of more complex molecules. Its unique halogenated structure may provide specific reactivity or properties that are valuable in the development of pharmaceuticals, agrochemicals, or other specialty chemicals.
Used in Pharmaceutical Industry:
1-(4-Bromo-2,6-difluoro-phenyl)-ethanone is used as a building block for the synthesis of pharmaceutical compounds, potentially offering novel therapeutic agents with unique mechanisms of action or improved pharmacokinetic properties.
Used in Agrochemical Industry:
1-(4-Bromo-2,6-difluoro-phenyl)-ethanone is used as a precursor in the development of agrochemicals, such as pesticides or herbicides, where its halogenated structure may contribute to enhanced biological activity or selectivity.
Used in Scientific Research:
1-(4-Bromo-2,6-difluoro-phenyl)-ethanone is used as a research tool in academic and industrial laboratories, where its reactivity and properties are studied to gain insights into chemical reactions and mechanisms, or to develop new synthetic methodologies.

Upstream product

• 184910-20-1 (4-bromo-2,6-difluoro-phenyl)-trimethyl-silane 
• 75-36-5 acetyl chloride 
• 183065-68-1 4-bromo-2,6-difluorobenzoic acid 
• 75-16-1 methylmagnesium bromide 
• 461-96-1 3,5-difluorobromobenzene 
• 108-24-7 acetic anhydride 

Downstream Products

• 746630-35-3 2-bromo-1-(4-bromo-2,6-difluorophenyl)ethan-1-one 

Relevant articles and documents

P2X3 MODULATORS

Provided herein are P2X3 modulators and methods of utilizing P2X3 modulators in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.

PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy

GPR120 agonists have therapeutic potential for the treatment of diabetes, but few selective agonists have been reported. We identified an indazole-6-phenylcyclopropylcarboxylic acid series of GPR120 agonists and conducted SAR studies to optimize GPR120 potency. Furthermore, we identified a (S,S)-cyclopropylcarboxylic acid structural motif which gave selectivity against GPR40. Good oral exposure was obtained with some compounds displaying unexpected high CNS penetration. Increased MDCK efflux was utilized to identify compounds such as 33 with lower CNS penetration, and activity in oral glucose tolerance studies was demonstrated. Differential activity was observed in GPR120 null and wild-type mice indicating that this effect operates through a mechanism involving GPR120 agonism.

PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted heteroaryls of formula 1 or of formula 1' wherein A is either N or CH, wherein R2 is selected from the group consisting of -C1-3-alkyl, -C1-3-haloalkyl, F, Br, CI, wherein Y is selected from -O- or -CH2-, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.

ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES

Aminothiazole compounds substituted with sulfur-containing groups are represented by the Formula (I), and their pharmaceutically acceptable salts, prodrugs, active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.